Mystery Spraying Solved?
Is This What's Going On?
The following data is profoundly interesting and may offer an answer to the
ongoing mystery of the spraying of American citizens from the air. The source
has asked to remain anonymous.
Aerosolized Vaccines And Contrails
This company, Maxygen, has been given a 6.7 million dollar grant from DARPA for the development of "aerosolized vaccines." Hhhhmmm. Interestingly, they are also working on an aerosolized anti-biological agent consisting of the commonly used protease, "subtilisin." This is an enzyme commonly found in laundry detergents. It has been found to be highly effective in beaking down bacterial cellular walls, causing the bacteria to literally explode into a harmless mass. The idea would be to spray any affected area or individuals with this enzyme foam and decontaminate them, without the need for toxic substances like formaldehyde. Apparently, it workd quite effectively. These clues may point towards an explanation of these strange contrails we've been witnessing all over the country.
DARPA Research And Development
The Program Manager is a Navy SEAL and MD, with the rank of Commander, Shaun Jones. Jones is known as "The Man from DARPA." I think the trail to solving the mystery contrails leads here. Just my hunch.
The goal of the Unconventional Pathogen Countermeasures program is to develop and demonstrate defensive technologies that afford the greatest protection to uniformed warfighters, and the defense personnel who support them, during U.S. military operations. While no defense may stop a determined adversary from unleashing biological weapon, a sufficiently robust array of pathogen defenses and countermeasures " deterrents in their own right " will reduce the probable damage that would result from biological weapons used in a particular operation.
The most sinister offensive biological warfare scenario employs surprise, immediate proximity, and rapidly lethal, persistent agents in overwhelming quantities. Under these circumstances, real-time sensing, donning of physical protection, and conventional nonmedical countermeasures are only marginally effective. An effective operational defense ideally requires instantly available or emplaced countermeasures that can defeat biological threats as they enter the body and before they reach and attack target cells and tissues.
The focus of the Unconventional Pathogen Countermeasures program is the development of revolutionary, broad-spectrum, medical countermeasures against significantly pathogenic microorganisms and/or their pathogenic products. These countermeasures will be versatile enough to eliminate biological threats, whether from natural sources or modified through bioengineering or other manipulation. They will also have the potential to provide protection both within the body and at the most common portals of entry (e.g., inhalation, ingestion, transcutaneous). Strategies include but are not limited to:
* Defeat of a pathogen's ability to enter the body, traverse the bloodstream or lymphatics, and enter target tissues.
* Identification of novel pathogen vulnerabilities based on fundamental, critical molecular mechanisms of survival or pathogenesis (e.g., Type III secretion, cellular energetics, virulence modulation).
* Construction of unique, robust vehicles for the delivery of countermeasures into or within the body.
* Modulation of the advantageous and/or deleterious aspects of the immune response to significantly pathogenic microorganisms and/or their pathogenic products in the body.
Decontamination Methods Based On Industrial Enzymes Optimized for Killing of Biological Warfare (BW) Spores
Maxygen, Inc. Redwood City, CA
Willem Stemmer, (Principal Investigator) Pascal Longchamp, Scientific Project Leader, Maxygen Inc. < Lori Giver, Scientist, Maxygen Inc. Jon Ness, Scientist, Maxygen Inc. Mark Welch, Scientist, Maxygen Inc. Anders Pedersen, Scientific Project Leader, Novo Nordisk A/S
The goal of the Maxygen/Novo collaborative DARPA project is to create decontamination reagents for Biological Warfare (BW) pathogens using a powerful new platform technology, DNA shuffling. DNA shuffling is a revolutionary method for directed evolution. Maxygen uses a preferred format, called family shuffling, to create large libraries of chimaeric genes encoding industrial enzymes that will be screened for antimicrobial activity against spore forming BW pathogens. In this project we integrate Novo Nordisk's expertise in industrial enzyme technology and production with Maxygen's expertise in DNA shuffling and library screening technologies.
Pathogenic spore-forming bacteria like Bacillus anthracis, Clostridium botulinum, C. difficile, C. perfringens and C. tetani form spores which survive in harsh environmental conditions for extended periods of time. The spore nucleoid structure is surrounded by protective layers composed of peptidoglycan and proteins with unusual amino acids content. This structure provides unique resistance properties acting as a permeability barrier to prevent access to the underlying spore protoplast. Spores are able to survive exposure to chlorinated solvents, detergents, mechanical disruption, extreme temperatures, UV and ionizing radiation. These organisms can be bioengineered to maximize pathogenicity and the spores easily weaponized and stored. The possible use of spores in BW or terrorist activities argues for an enzyme-based, broad spectrum decontamination formulation for personnel, equipment and environment. Integration of our technologies and expertise will result in the development of effective spore-degrading enzymes and a novel platform for rapid enzyme development against a wide variety of wild-type and recombinant spore-forming BW pathogens.
Last Updated: Oct 20, 1998
Revealing DARPA Page Loaded With Intriguing References To Advanced BioWarfare And Related Research Many of which could have application via mass spraying and aerosolization. (Go to this page to access direct links to any of the topics listed below)
Anti-Bacterials Anti-Toxins Anti-Viral Decontamination External Protection Immunization Multi-Purpose
Anti-Bacterials Sweden Defence Research Establishment (FOA) Umeå, Sweden
Common Signatures of Infected Eukaryotic Cells U.S. Harvard Medical School Boston, MA
To Exploit the Essential Cell Division Protein FtsZ as a Broad-Spectrum Anti-Bacterial Target U.S. Ibis Therapeutics Carlsbad, CA
Universal Pathogen Countermeasures U.S. Isis Pharmaceuticals Carlsbad, CA <
Drugs to Protect Against Engineered Biological Warfare Bacteria U.S. SmithKline Beecham Pharmaceuticals Collegeville, PA
Novel Broad Spectrum Antimicrobial Agents - Gene Expression U.S. Stanford University Stanford, CA
Novel Targets of Pathogen Vulnerability U.S. Stanford University School of Medicine Stanford, CA
Common Targets of Pathogen Vulnerability
Anti-Toxins Israel The Hebrew University of Jerusalem Jerusalem, Israel
Superantigen Toxin Antagonist and Vaccine U.S. Los Alamos National Laboratory Los Alamos, NM
Structural Biology of Bacterial Toxins U.S. Rockefeller University New York, NY
Rapid Method to Express Biologically Active Proteins on the Surface of Gram-Positive Bacteria for Biological and Vaccine Purposes U.S. Stanford University Stanford, CA
Creating Cellular Resistance to Toxins in Mammals
Anti-Viral U.S. enVision Cherry Hill, NJ
Developmental Proteins to Prevent Human Injury from Pathogens U.S. Genelabs Technologies, Inc. Redwood City, CA
Stockpiling Drug Subunits for Rapid Response to Biological Warfare U.S. Hughes Institute Saint Paul, MN
Pokeweed Antiviral Protein as a Universal Virus Neutralizer U.S. The Scripps Research Institute La Jolla, CA
Invasive (Intra-cellular) Antibodies U.S. Stanford University School of Medicine Stanford, CA
A Common Target for Positive-Strand RNA Viruses U.S. University of Texas Medical Branch at Galveston Galveston, TX
Structure-based Design of Acute Countermeasures to Viruses U.S. University of Wisconsin Madison, WI
Non-Peptide Antiviral Agents that Interdict Host Cell Transport U.S. Xavos San Francisco, CA
Intraneuronal Drug Delivery
Decontamination U.S. Maxygen, Inc. Redwood City, CA
Decontamination Methods Based on Industrial Enzymes Optimized for Killing of Biological Warfare (BW) Spores U.S. University of Michigan Ann Arbor, MI
Molecular Decoys to Soak up Pathogens
External Protection U.S. Harvard University Cambridge, MA
Polyvalent Inhibitors of Adhesion of Microorganisms, Viruses, and Toxins U.S. Molecular Geodesics Inc. Boston, MA
Biomimetic Materials for Pathogen Neutralization U.S. Northrop Grumman Corporation Bethpage, NY
Personal Environmental Protection System
Immunization U.S. Boyce Thompson Institute for Plant Research, Inc. Ithaca, NY
High Level Expression of Vaccine Antigens and Epithelial Transport Molecules In Transgenic Plant Cells and Organs U.S. Harvard University Boston, MA
Novel Bacteriophage Therapies for Vibrio cholerae Infection U.S. Massachusetts General Hospital /Harvard Medical School Boston, MA
Super Immune Cells U.S. Maxygen, Inc. Redwood City, CA
Improved Vaccines by DNA Shuffling of Pathogen Antigens U.S. OSIRIS Therapeutics, Inc. Baltimore, MD
Sequential Auto Vaccination by Stem Cells U.S. University of Connecticut School of Medicine Farmington, CT
Heat Shock Protein-Peptide Complexes as Anti-Viral Agents U.S. University of Texas-Southwestern Medical Center Dallas, TX
Instant Immunization
Multi-Purpose U.S. Abitis Pharmaceuticals LLC Dallas, TX
Neuroimmunomodulatory alpha-MSH peptides U.S. Alnis, LLC San Leandro, CA
Novel Pathogen Countermeasures via Molecular and Nano-Surface Recognition U.S. Boston University Boston, MA
Red Blood Cell Pathogen Defense - Destruction U.S. ChemoCentryx San Carlos, CA
Development of Novel Dendritic Cell-Active Chemokine Modalities and Advanced Cell Detection Technologies for Intensified Vaccination and Accelerated Immunotherapy U.S. GeneSoft, Inc. South San Francisco, CA
Genetic Countermeasures: Regulation of Pathogen Gene Expression by DNA-Binding Polyamides U.S. Inotek Corporation Beverly, MA
Mercaptoethylguanidine: A Revolutionary Generic Immunomodulatory Countermeasure for Biological Warfare Defense U.S. Maxygen, Inc. Redwood City, CA
Genetic Vaccine Vectors Evolved for Optimal Immunization with Pathogen Antigens U.S. Rush Medical Center Chicago, IL
Ionic Channels U.S. University of Michigan Ann Arbor, MI
Intracellular Sensors of Virulence U.S. University of Iowa Iowa City, IA
Activation of Innate Immunity by CpG DNA for Broad Spectrum Protection Against Pathogens U.S. University of Texas-Southwestern Medical Center Dallas, TX
Paraimmunity, Super Vaccines, and Chemical Genomics U.S. University of Virginia School of Medicine Charlottesville, VA
Red Blood Cell Pathogen Defense - Decoy